Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2/CD56 Bi-specific CAR-T Cells for Cancer Treatment
NCT05437328Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Number of patients with adverse events at 6 months. Started Jun 2026; status: terminated.
02
Conditions
cancer
Beyond the preview
Go deeper on NCT05437328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437328.